Overview

Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus

Status:
Not yet recruiting
Trial end date:
2024-03-14
Target enrollment:
Participant gender:
Summary
The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus. Participants will be treated for 4 or 12 weeks followed by an 8 week follow-up period
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals